Which has stronger valuation & earnings, TLX or AXSM?

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.26 -$7.12M N/A N/A Axsome Therapeutics $638.50M 20.19 -$183.17M -$3.73 N/A

Does the media prefer TLX or AXSM?

In the previous week, Axsome Therapeutics had 14 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 16 mentions for Axsome Therapeutics and 2 mentions for Telix Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.18 beat Telix Pharmaceuticals' score of 0.66 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TLX or ELAN?

Telix Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.26 -$7.12M N/A N/A Elanco Animal Health $4.72B 2.56 -$232M -$0.50 N/A

Does the media prefer TLX or ELAN?

In the previous week, Elanco Animal Health had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 2 mentions for Telix Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.85 beat Telix Pharmaceuticals' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, TLX or SMMT?

Telix Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.26 -$7.12M N/A N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is TLX or SMMT more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Summit Therapeutics N/A -291.24% -243.07%

Does the media prefer TLX or SMMT?

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 2 mentions for Telix Pharmaceuticals and 1 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat Telix Pharmaceuticals' score of 0.66 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TLX or RDY?

Telix Pharmaceuticals presently has a consensus price target of $21.13, suggesting a potential upside of 109.37%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telix Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings & valuation, TLX or RDY?

Dr. Reddy's Laboratories has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.26 -$7.12M N/A N/A Dr. Reddy's Laboratories $3.58B 3.11 $456M $0.58 22.96

Which has stronger valuation and earnings, TLX or ARWR?

Arrowhead Pharmaceuticals has higher revenue and earnings than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.26 -$7.12M N/A N/A Arrowhead Pharmaceuticals $829.45M 13.89 -$1.63M -$2.15 N/A

Telix Pharmaceuticals (TLX) Competitors

$10.09 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$9.79 -0.30 (-2.96%)

As of 06/18/2026 05:30 PM Eastern

Compare

TLX vs. AXSM, ELAN, SMMT, RDY, and ARWR

Should you buy Telix Pharmaceuticals stock or one of its competitors? MarketBeat compares Telix Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Telix Pharmaceuticals include Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Telix Pharmaceuticals has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Telix Pharmaceuticals' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Telix Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.26	-$7.12M	N/A	N/A
Axsome Therapeutics	$638.50M	20.19	-$183.17M	-$3.73	N/A

Telix Pharmaceuticals presently has a consensus target price of $21.13, suggesting a potential upside of 109.37%. Axsome Therapeutics has a consensus target price of $258.95, suggesting a potential upside of 3.37%. Given Telix Pharmaceuticals' higher possible upside, research analysts plainly believe Telix Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 14 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 16 mentions for Axsome Therapeutics and 2 mentions for Telix Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 1.18 beat Telix Pharmaceuticals' score of 0.66 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Summary

Axsome Therapeutics beats Telix Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Telix Pharmaceuticals (NASDAQ:TLX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Telix Pharmaceuticals has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Elanco Animal Health	-4.95%	7.42%	3.66%

Telix Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.26	-$7.12M	N/A	N/A
Elanco Animal Health	$4.72B	2.56	-$232M	-$0.50	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Telix Pharmaceuticals has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

In the previous week, Elanco Animal Health had 8 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Elanco Animal Health and 2 mentions for Telix Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.85 beat Telix Pharmaceuticals' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals currently has a consensus price target of $21.13, suggesting a potential upside of 109.37%. Elanco Animal Health has a consensus price target of $28.55, suggesting a potential upside of 17.91%. Given Telix Pharmaceuticals' higher possible upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Elanco Animal Health beats Telix Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Telix Pharmaceuticals (NASDAQ:TLX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Telix Pharmaceuticals has higher revenue and earnings than Summit Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.26	-$7.12M	N/A	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Telix Pharmaceuticals presently has a consensus target price of $21.13, suggesting a potential upside of 109.37%. Summit Therapeutics has a consensus target price of $27.23, suggesting a potential upside of 98.00%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 2 mentions for Telix Pharmaceuticals and 1 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.12 beat Telix Pharmaceuticals' score of 0.66 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Telix Pharmaceuticals' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Summit Therapeutics	N/A	-291.24%	-243.07%

Summary

Telix Pharmaceuticals beats Summit Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Telix Pharmaceuticals (NASDAQ:TLX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Dr. Reddy's Laboratories has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.26	-$7.12M	N/A	N/A
Dr. Reddy's Laboratories	$3.58B	3.11	$456M	$0.58	22.96

Telix Pharmaceuticals presently has a consensus price target of $21.13, suggesting a potential upside of 109.37%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Telix Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Telix Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Telix Pharmaceuticals has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 2 mentions for Telix Pharmaceuticals and 0 mentions for Dr. Reddy's Laboratories. Telix Pharmaceuticals' average media sentiment score of 0.66 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telix Pharmaceuticals	Positive
Dr. Reddy's Laboratories	Neutral

Summary

Dr. Reddy's Laboratories beats Telix Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Arrowhead Pharmaceuticals has higher revenue and earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.26	-$7.12M	N/A	N/A
Arrowhead Pharmaceuticals	$829.45M	13.89	-$1.63M	-$2.15	N/A

Telix Pharmaceuticals has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 10 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 2 mentions for Telix Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.31 beat Telix Pharmaceuticals' score of 0.66 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals currently has a consensus price target of $21.13, indicating a potential upside of 109.37%. Arrowhead Pharmaceuticals has a consensus price target of $86.36, indicating a potential upside of 5.55%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Telix Pharmaceuticals has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Telix Pharmaceuticals' return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Arrowhead Pharmaceuticals beats Telix Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Telix Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLX vs. The Competition

Export

Metric	Telix Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.42B	$3.41B	$6.65B	$12.60B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	N/A	19.73	24.75	24.42
Price / Sales	4.26	320.32	529.30	111.09
Price / Cash	239.31	56.54	27.92	37.84
Price / Book	8.20	8.15	10.81	6.60
Net Income	-$7.12M	$23.91M	$3.57B	$337.10M
7 Day Performance	5.54%	2.57%	0.72%	0.83%
1 Month Performance	-1.75%	0.69%	0.41%	2.25%
1 Year Performance	-41.17%	55.09%	29.34%	36.14%

Telix Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLX Telix Pharmaceuticals	4.2873 of 5 stars	$10.09 flat	$21.13 +109.4%	-41.2%	$3.42B	$803.79M	N/A	1,184	Positive News
AXSM Axsome Therapeutics	2.2788 of 5 stars	$237.18 +2.1%	$251.26 +5.9%	+148.8%	$12.25B	$638.50M	N/A	380	News Coverage Positive News Analyst Forecast Gap Up
ELAN Elanco Animal Health	3.7804 of 5 stars	$24.48 +3.4%	$28.20 +15.2%	+79.8%	$12.23B	$4.72B	N/A	9,400	News Coverage Positive News Analyst Forecast Gap Up
SMMT Summit Therapeutics	3.8456 of 5 stars	$14.28 +1.2%	$26.05 +82.5%	-33.1%	$11.21B	N/A	N/A	110	Positive News Gap Up
RDY Dr. Reddy's Laboratories	1.2503 of 5 stars	$13.26 +0.2%	N/A	-12.5%	$11.07B	$335.93B	22.87	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLX) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Telix Pharmaceuticals (TLX) Competitors

TLX vs. AXSM, ELAN, SMMT, RDY, and ARWR

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Telix Pharmaceuticals (TLX) Competitors

TLX vs. AXSM, ELAN, SMMT, RDY, and ARWR

How does Telix Pharmaceuticals compare to Axsome Therapeutics?

Is TLX or AXSM more profitable?

Which has stronger valuation & earnings, TLX or AXSM?

Do analysts prefer TLX or AXSM?

Do insiders & institutionals hold more shares of TLX or AXSM?

Does the media prefer TLX or AXSM?

Which has more risk and volatility, TLX or AXSM?

Summary

How does Telix Pharmaceuticals compare to Elanco Animal Health?

Is TLX or ELAN more profitable?

Which has better earnings and valuation, TLX or ELAN?

Do institutionals and insiders hold more shares of TLX or ELAN?

Which has more volatility and risk, TLX or ELAN?

Does the media prefer TLX or ELAN?

Do analysts prefer TLX or ELAN?

Summary

How does Telix Pharmaceuticals compare to Summit Therapeutics?

Which has higher valuation & earnings, TLX or SMMT?

Do analysts rate TLX or SMMT?

Do institutionals & insiders hold more shares of TLX or SMMT?

Does the media prefer TLX or SMMT?

Which has more volatility and risk, TLX or SMMT?

Is TLX or SMMT more profitable?

Summary

How does Telix Pharmaceuticals compare to Dr. Reddy's Laboratories?

Which has higher earnings & valuation, TLX or RDY?

Do analysts prefer TLX or RDY?

Is TLX or RDY more profitable?

Do institutionals and insiders have more ownership in TLX or RDY?

Which has more volatility and risk, TLX or RDY?

Does the media refer more to TLX or RDY?

Summary

How does Telix Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Which has stronger valuation and earnings, TLX or ARWR?

Which has more volatility & risk, TLX or ARWR?

Does the media prefer TLX or ARWR?

Do analysts prefer TLX or ARWR?

Do institutionals & insiders believe in TLX or ARWR?

Is TLX or ARWR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX vs. The Competition

Telix Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools